| *Sponsored by Alzamend Neuro, Inc.
(Nasdaq: ALZN) Jumps Vertically On Breaking News Thursday (Triple-Digit Move In Pre-Market)
May 29th Greetings, Friend!
Alzamend Neuro, Inc. (Nasdaq: ALZN) is making moves early Thursday and it may just be the start.
Since an approx. valuation of $3.50 at 8:00AM EST today, ALZN has been on a heater, running to a pre-market high of $8.80 at the time writing.
What has caused this triple-digit run? Part of it could be due to the company's major breaking news today. Take a look:
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Topline data expected by year end
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), ..., today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
...
“The dosing of the first patient in our first Phase II trial of AL001 is another significant step forward in our goal to introduce a next-generation lithium treatment that offers enhanced safety, better central nervous system targeting, and eliminates the requirement for TDM,” stated Stephan Jackman, Chief Executive Officer of Alzamend. “This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD and PTSD. We expect to announce topline data from this study before the end of 2025.”
Read the full article here.
With a low float of fewer than 1Mn shares according to MarketWatch, volatility potential could be heightened after today's news.
Take a moment to quickly review the report below and consider (Nasdaq: ALZN) for your watchlist today. -----
The neurodegenerative disease care industry is evolving.
New treatments targeting Alzheimer’s, bipolar disorder ("BD"), major depressive disorder ("MDD"), and post-traumatic stress disorder ("PTSD") are gaining attention.
Here's why I bring it up...
One under-the-radar, clinical-stage biopharma company has begun a Phase II trial using a novel lithium delivery method, aiming for safer, more effective treatments that could remove the need for lithium drug monitoring.
Earlier pre-clinical studies showed better brain absorption in mice, the company is now looking to demonstrate the same in human brains...
With these advances and ongoing unmet needs, this company could be worth paying close attention to as its Phase II trial progresses.
Here's another reason to watch this Nasdaq-listed company is its very low float—under 1Mn shares—suggests strong volatility potential may be present daily.
Consider adding this Nasdaq idea to your watchlist: Alzamend Neuro, Inc. (Nasdaq: ALZN)
Alzamend Neuro is a clinical-stage biopharmaceutical company developing new therapies for Alzheimer’s, BD, MDD, and PTSD.
Its mission is to rapidly bring safe, effective treatments to market.
Headquartered in Atlanta, Alzamend’s pipeline includes two drug candidates licensed from the University of South Florida.
The lead candidate, AL001, uses a patented ionic cocrystal technology to deliver lithium with improved safety and efficacy. Preclinical and early clinical studies show AL001 may prevent cognitive deficits and improve mood with fewer side effects than traditional lithium. Phase I and II trials have shown bioequivalence and good safety; topline results from the Phase IIA trial in Alzheimer’s patients were announced in June 2023.
Therefore, new indications added in 2H 2024 for BD, MDD, and PTSD were able to bypass Phase I studies and go directly to Phase II.
Alzamend’s second candidate, ALZN002, is an “active” immunotherapy using each patient’s dendritic cells to target Alzheimer’s-related amyloid-beta proteins. A Phase I/IIA trial began in March 2023 after FDA authorization.
Alzamend’s work comes as Alzheimer’s cases and costs rise sharply in the U.S., with over 6 million affected and costs projected to reach $1.1Tn by 2050.
Through its innovative pipeline, Alzamend Neuro aims to reshape Alzheimer’s and psychiatric disorder treatment and provide hope for millions.
Grab Sources Right Here: Company Website. Company Presentation. -----
4 Quick Reasons To Consider (Nasdaq: ALZN) For Your Watchlist
No. 1 - ALZN has a low float.
MarketWatch is reporting ALZN to have a float of roughly 767.17k shares.
That float size could lead to an environment of heightened volatility potential.
No. 2 - An analyst target may suggest massive upside potential.
On March 15th this year, an Ascendiant Capital Markets analyst set a price target of $20 for ALZN.
When this target was issued, ALZN shares were priced near $0.68—prior to the company’s reverse split on May 8th.
This price target implies that ALZN may have had a potential upside of more than 2,800% at that point.
Read the full analyst report for more details.
No. 3 - Alzamend Neuro Begins Phase II Clinical Trial.
Alzamend Neuro has enrolled its first patient in a Phase II clinical trial of AL001, a novel lithium-based treatment for Alzheimer’s, at Massachusetts General Hospital, aiming for improved brain delivery and safety over current lithium therapies.
No. 4 - Alzamend Neuro Partners With QMENTA For Imaging.
Alzamend Neuro has partnered with QMENTA to utilize advanced neuroimaging and AI technology in its clinical trials, enhancing data analysis and supporting the development of treatments for neurodegenerative diseases. -----
It's official. Coverage has been initiated on Alzamend Neuro, Inc. (Nasdaq: ALZN).
Be on the lookout for updates moving forward. Talk again soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/29/2025 and ending on 05/29/2025 to publicly disseminate information about (ALZN:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Alzamend Neuro Inc., the issuer of (ALZN:US).
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ALZN:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/alzn-foqsa/#details | 
0 Response to "(Nasdaq: ALZN) Jumps Vertically On Breaking News Thursday (Triple-Digit Move In Pre-Market)"
Post a Comment